Fulgent Genetics Stock Forecast, Price & News

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fulgent Genetics in the last year. There are currently 1 sell rating, 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Fulgent Genetics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FLGT, but not buy additional shares or sell existing shares.
View analyst ratings for Fulgent Genetics or view top-rated stocks.

Wall Street analysts have given Fulgent Genetics a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Fulgent Genetics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Fulgent Genetics is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021.
View our earnings forecast for Fulgent Genetics.

Fulgent Genetics, Inc. (NASDAQ:FLGT) issued its quarterly earnings data on Thursday, May, 6th. The company reported $6.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.95 by $0.64. The business earned $359.43 million during the quarter, compared to analyst estimates of $326.46 million. Fulgent Genetics had a net margin of 53.91% and a trailing twelve-month return on equity of 101.08%. The business's revenue for the quarter was up 4536.0% compared to the same quarter last year.
View Fulgent Genetics' earnings history.

Fulgent Genetics' stock was trading at $10.06 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, FLGT stock has increased by 677.2% and is now trading at $78.19.
View which stocks have been most impacted by COVID-19.

Fulgent Genetics updated its second quarter 2021 earnings guidance on Thursday, May, 27th. The company provided earnings per share (EPS) guidance of - for the period. The company issued revenue guidance of $200 million-$200 million, compared to the consensus revenue estimate of $193.95 million.

5 analysts have issued 1-year price objectives for Fulgent Genetics' stock. Their forecasts range from $40.00 to $140.00. On average, they anticipate Fulgent Genetics' share price to reach $88.00 in the next twelve months. This suggests a possible upside of 12.5% from the stock's current price.
View analysts' price targets for Fulgent Genetics or view top-rated stocks among Wall Street analysts.

Some companies that are related to Fulgent Genetics include Invitae (NVTA), Elekta AB (publ) (EKTAY), CareDx (CDNA), Burning Rock Biotech (BNR), Veracyte (VCYT), Genetron (GTH), Castle Biosciences (CSTL), RadNet (RDNT), DermTech (DMTK), Renalytix AI (RNLX), Personalis (PSNL), Celcuity (CELC), Exagen (XGN), Centogene (CNTG) and Progenity (PROG).
View all of FLGT's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Fulgent Genetics investors own include NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Inseego (INSG), NeoGenomics (NEO), Invitae (NVTA), Square (SQ), JD.com (JD), Marvell Technology (MRVL), Teladoc Health (TDOC) and Editas Medicine (EDIT).

(FLGT) raised $60 million in an IPO on Thursday, September 29th 2016. The company issued 4,600,000 shares at a price of $12.00-$14.00 per share. Credit Suisse and Piper Jaffray acted as the underwriters for the IPO and Raymond James and BTIG were co-managers.

Fulgent Genetics trades on the NASDAQ under the ticker symbol "FLGT."

Fulgent Genetics' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.92%), Morgan Stanley (1.92%), Baker BROS. Advisors LP (1.38%), Geode Capital Management LLC (0.92%), Nepsis Inc. (0.66%) and Northern Trust Corp (0.64%). Company insiders that own Fulgent Genetics stock include Hanlin Gao, Jian Xie, John C Bolger and Paul Kim.
View institutional ownership trends for Fulgent Genetics.

FLGT stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Baker BROS. Advisors LP, Nepsis Inc., Credit Suisse AG, Essex Investment Management Co. LLC, Victory Capital Management Inc., Concorde Asset Management LLC, and Los Angeles Capital Management LLC. Company insiders that have sold Fulgent Genetics company stock in the last year include Hanlin Gao, Jian Xie, John C Bolger, and Paul Kim.
View insider buying and selling activity for Fulgent Genetics or view top insider-selling stocks.

FLGT stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Morgan Stanley, Geode Capital Management LLC, Man Group plc, JPMorgan Chase & Co., Principal Financial Group Inc., Principal Financial Group Inc., and Ameriprise Financial Inc..
View insider buying and selling activity for Fulgent Genetics or or view top insider-buying stocks.

Shares of FLGT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of FLGT stock can currently be purchased for approximately $78.19.

Fulgent Genetics has a market capitalization of $2.27 billion and generates $421.71 million in revenue each year. The company earns $214.31 million in net income (profit) each year or $8.85 on an earnings per share basis.

Fulgent Genetics employs 700 workers across the globe.

The official website for Fulgent Genetics is www.fulgentgenetics.com.

Fulgent Genetics is headquartered at 4978 SANTA ANITA AVENUE, TEMPLE CITY CA, 91780.

Fulgent Genetics' mailing address is 4978 SANTA ANITA AVENUE, TEMPLE CITY CA, 91780. The company can be reached via phone at 626-350-0537 or via email at [email protected]